[Highly selective virostatic therapy. Influenza wave could have been stopped].
Leshel-Hauzeneder
Melanie
M
D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016207:Cytokines / Q000097:blood; D004730:Endothelium, Vascular / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005340:Fibrinogen / Q000032:analysis; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007251:Influenza, Human / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000503:physiopathology; D009439:Neuraminidase / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D053139:Oseltamivir; D010919:Placebos; D013997:Time Factors; D016896:Treatment Outcome
D000081:Acetamides; D000998:Antiviral Agents; D016207:Cytokines; D004791:Enzyme Inhibitors; D010919:Placebos; D053139:Oseltamivir; D005340:Fibrinogen; D009439:Neuraminidase